Trial Profile

Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in Diabetic Macular Edema Patients Treated With Aflibercept (FORESIGHT)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary)
Indications Diabetic macular oedema
Focus Therapeutic Use
Acronyms FORESIGHT

Most Recent Events

28 May 2024 Status changed from recruiting to completed.
21 Sep 2020 Planned End Date changed from 1 Oct 2020 to 1 Sep 2022.
21 Sep 2020 Planned primary completion date changed from 1 Jan 2020 to 30 Nov 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com